课题基金 / 基金详情

ANTIGENIC STRUCTURE OF HEPATITIS C VIRUS

ANTIGENIC STRUCTURE OF HEPATITIS C VIRUS
丙型肝炎病毒的抗原结构
批准号:
5200720
负责人:
S M FEINSTONE
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

S M FEINSTONE的其他基金

相似基金

相关文献

中文摘要
翻译
对丙型肝炎病毒的T细胞和B细胞免疫反应正在研究中。 在此之前,我们开发并鉴定了人类和小鼠的单克隆 抗丙型肝炎病毒结构基因的抗体;使用重组 杆状病毒表达抗原。我们已经证明,针对人类的抗体 E1和E2可与天然病毒粒子结合,抗核心抗体可与天然病毒粒子结合 病毒粒子被洗涤剂从包膜上剥离。T细胞研究是 继续努力鉴定细胞毒性T细胞和辅助T细胞 细胞表位。我们正在研究增殖性和CTL反应 慢性丙型肝炎患者对多肽抗原和抗原的感染 通过重组DNA系统进行表达。我们之前发现了一种CTL 核心区的表位,小鼠和人类都能识别。 使用预测的来自丙型肝炎病毒多蛋白的HLAA2基序,我们鉴定了 另外5个表位,3个位于核心蛋白,1个位于NS4B,1个位于NS5B。 我们发现慢性丙型肝炎病毒感染者的人类白细胞抗原A2对AT有反应。 CTL检测中至少有一个表位,但有2名患者 从丙型肝炎病毒中恢复的患者没有反应。我们还开发了一种新的方法 以识别不依赖于已知选择的CTL表位 图案。我们对纯化的丙型肝炎病毒NS3蛋白进行了蛋白水解性消化 用高效液相色谱分离得到的多肽。每个片段都被用来 脉冲同基因靶细胞和CTL中识别的靶细胞 测定结果进行了测序。然后,精确的表位由 合成覆盖反应肽的重叠十肽。 我们在NS3蛋白中发现了一个新的表位, 慢性丙型肝炎病毒感染会有反应。这个表位也只有 表达人类白细胞抗原A2的患者,即使该多肽不包含 识别的A2结合基序。实验性丙型肝炎病毒基因疫苗 正在研究中。BALB/c小鼠被证明在 注射表达丙型肝炎病毒E2的质粒组。我们已经延长了这些 实验包括丙型肝炎病毒核心基因和E1基因以及E2基因。 接种的小鼠对特定的丙型肝炎病毒既有抗体又有CTL反应 抗原。体外免疫相关性正在开发中,它将 协助评估这些基于质粒基的疫苗。其他内容 现在正在评估包括细胞因子基因的结构 非结构基因和非结构基因的表达以及特异性CTL表位 非特定辅助表位。
英文摘要
Both T cell and B cell immune responses to HCV are being investigated. Previously we developed and characterized human and mouse monoclonal antibodies to the HCV structural genes; core, E1 and E2 using recombinant baculovirus expressed antigens. We have shown that the antibodies to E1 and E2 can bind to native virion and antibody to core can bind to virion stripped of its envelope by detergent. T cell studies are continuing in an effort to identify both cytotoxic T cell and helper T cell epitopes. We are studying the proliferative and CTL responses of patients with chronic HCV infections to peptide antigens and antigens expressed by recombinant DNA systems. We previously identified a CTL epitope in the core region that is recognized by both mice and humans. Using predicted HLA A2 motifs from the HCV polyprotein, we identified five additional epitopes, 3 in the core protein, 1 in NS4B and 1 in NS5B. We found that HLA A2 patients with chronic HCV infections react to at least one of these epitopes in CTL assays but that 2 patients who had recovered from HCV did not react. We have also developed a new approach to identifying CTL epitopes that is not dependent on selecting for known motifs. We made proteolytic digests purified HCV NS3 protein and separated the resulting peptides by HPLC. Each fraction was used to pulse syngenetic target cells and those that were recognized in a CTL assay were sequenced. The precise epitope was then mapped by synthesizing overlapping decapeptides that covered the reactive peptide. We identified a new epitope in the NS3 protein to which patients with chronic HCV infections react. This epitope was also recognized only by patients who expressed HLA A2 even though the peptide did not contain a recognized A2 binding motif. Experimental genetic vaccines against HCV are being studied. BALB/c mice have been shown to develop antibody after injection with a plasmid that expresses HCV E2. We have extended these experiments to include the HCV core and E1 genes as well as E2. Inoculated mice exhibit both antibody and CTL responses to specific HCV antigens. In vitro correlates of immunity are being developed that will assist in evaluation of these plasmid based vaccines. Additional constructs are now being evaluated that include genes for cytokine expression as well as specific CTL epitopes from non-structural genes and non-specific helper epitopes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HYBRIDOMA ANTIBODIES TO PATHOGENIC VIRUSES
HEPATITIS C VIRUS NEUTRALIZATION METHOD DEVELOPMENT
  • 批准号:
    6101194
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    S M FEINSTONE
  • 依托单位:
    --
STRUCTURAL AND ANTIGENIC ANALYSIS OF HEPATITIS A VIRUS
ANTIGENIC STRUCTURE OF HEPATITIS A VIRUS
  • 批准号:
    3811272
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    S M FEINSTONE
  • 依托单位:
    --
海外基金